

Patient Information	Specimen Information	Client Information

**Cardio IQ®**

Test Name	Current		Risk/Reference Interval			Units	Historical
	Result & Risk		Optimal	Moderate	High		
	Optimal	Non-Optimal					
<b>INFLAMMATION</b>							
F2-ISOPROSTANE/CREATININE RATIO	<b>0.57</b>		<0.86	N/A	>=0.86	ng/mg Creat	
F2-ISOPROSTANE	<b>0.68</b>					ng/mL	
CREATININE, URINE	<b>119</b>			20-275		mg/dL	

For details on reference ranges please refer to the reference range/comment section of the report.

SPECIMEN:

Patient Information	Specimen Information	Client Information

**Reference Range/Comments**

Analyte Name	In Range	Out Range	Reference Range	Lab
CREATININE, URINE	119		20-275 mg/dL	
F2-ISOPROSTANE	0.68		ng/mL	
F2-ISOPROSTANE/CREAT RATIO	0.57		<0.86 ng/mg Creat	

Elevated urinary F2-Isoprostanes are associated with an increased relative risk of coronary heart disease (CHD) (1). (Reference: 1-Schwedhelm et al. Circulation. 2004; 109: 843-848). This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

SPECIMEN: